Another trial for the TARGET trial

Mohammad H Alshaer^{1

2}, Charles A Peloquin^{3

4}

Affiliations

¹ Infectious Disease Pharmacokinetics Laboratory, College of Pharmacy and Emerging Pathogens Institute, University of Florida, 1600 SW Archer Rd, Medical Science Building, PO Box 100486, Gainesville, FL, 32610, USA. mshaer@ufl.edu.
² Department of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, Gainesville, FL, USA. mshaer@ufl.edu.
³ Infectious Disease Pharmacokinetics Laboratory, College of Pharmacy and Emerging Pathogens Institute, University of Florida, 1600 SW Archer Rd, Medical Science Building, PO Box 100486, Gainesville, FL, 32610, USA.
⁴ Department of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, Gainesville, FL, USA.

Comment

Mohammad H Alshaer et al. Intensive Care Med. 2022 Jun.

. 2022 Jun;48(6):774-775.

doi: 10.1007/s00134-022-06654-9. Epub 2022 Mar 1.

Mohammad H Alshaer^{1

2}, Charles A Peloquin^{3

4}

¹ Infectious Disease Pharmacokinetics Laboratory, College of Pharmacy and Emerging Pathogens Institute, University of Florida, 1600 SW Archer Rd, Medical Science Building, PO Box 100486, Gainesville, FL, 32610, USA. mshaer@ufl.edu.
² Department of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, Gainesville, FL, USA. mshaer@ufl.edu.
³ Infectious Disease Pharmacokinetics Laboratory, College of Pharmacy and Emerging Pathogens Institute, University of Florida, 1600 SW Archer Rd, Medical Science Building, PO Box 100486, Gainesville, FL, 32610, USA.
⁴ Department of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, Gainesville, FL, USA.

No abstract available

Comment in

Another trial for the TARGET trial. Author's reply.
Hagel S, Pletz MW, Lehmann T. Hagel S, et al. Intensive Care Med. 2022 Jun;48(6):776-777. doi: 10.1007/s00134-022-06670-9. Epub 2022 Mar 23. Intensive Care Med. 2022. PMID: 35320369 Free PMC article. No abstract available.

Effect of therapeutic drug monitoring-based dose optimization of piperacillin/tazobactam on sepsis-related organ dysfunction in patients with sepsis: a randomized controlled trial.
Hagel S, Bach F, Brenner T, Bracht H, Brinkmann A, Annecke T, Hohn A, Weigand M, Michels G, Kluge S, Nierhaus A, Jarczak D, König C, Weismann D, Frey O, Witzke D, Müller C, Bauer M, Kiehntopf M, Neugebauer S, Lehmann T, Roberts JA, Pletz MW; TARGET Trial Investigators. Hagel S, et al. Intensive Care Med. 2022 Mar;48(3):311-321. doi: 10.1007/s00134-021-06609-6. Epub 2022 Feb 1. Intensive Care Med. 2022. PMID: 35106617 Free PMC article. Clinical Trial.

1. Hagel S, Bach F, Brenner T, Bracht H, Brinkmann A, Annecke T et al (2022) Effect of therapeutic drug monitoring-based dose optimization of piperacillin/tazobactam on sepsis-related organ dysfunction in patients with sepsis: a randomized controlled trial. Intensive Care Med 48:311–321 - DOI
1. Carrie C, Legeron R, Petit L, Ollivier J, Cottenceau V, d’Houdain N et al (2018) Higher than standard dosing regimen are needed to achieve optimal antibiotic exposure in critically ill patients with augmented renal clearance receiving piperacillin-tazobactam administered by continuous infusion. J Crit Care 48:66–71 - DOI